{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:21:23Z","timestamp":1761488483196},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":4741,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1996,5]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> Thirteen consecutive adult patients with primary refractory (<jats:italic>n<\/jats:italic> = 5) or relapsed (<jats:italic>n<\/jats:italic> = 8) acute lymphoblastic leukemia (ALL) were treated by an induction schedule (FLAG) consisting of Fludarabine (30 mg\/sqm\/d) plus high dose Cytarabine (HD\u2010ara\u2010C: 2 g\/sqm\/d) (d 1\u20135) and G\u2010CSF (from d 0 to polymorphonuclear recovery). Patients achieving complete remission (CR) were administered a second FLAG course as consolidation and were then submitted to an individualized program of post\u2010remission therapy, depending on the patient's age and performance status. CR was achieved in 8\/12 evaluable cases (67%). The median CR duration was 22.5 w. CR attainment was significantly related to the co\u2010expression of lymphoid and myeloid antigens. ALL\/My+ patients achieved CR in 6\/6 evaluable cases vs. 2\/6 for ALL\/My<jats:sup>\u2010<\/jats:sup>. <jats:italic>In vitro<\/jats:italic> <jats:sup>3<\/jats:sup>H ara\u2010C incorporation into cellular DNA resulted significantly increased by Fludarabine (in 7\/9 tested cases) and, furthermore, by the association of Fludarabine\u2010G\u2010CSF in 5 evaluable ALL\/My+ cases; in contrast, no effect of G\u2010CSF addition to Fludarabine was observed in 4 ALL\/My<jats:sup>\u2013<\/jats:sup>. Myelosuppression was observed in all patients: the median time to neutrophils &gt;0.5 \u00d7 10<jats:sup>9<\/jats:sup>\/l was 16.3 d (range 13\u201322) and 16.2 d (range 9\u201329) to platelets&gt;20 \u00d7 10<jats:sup>9<\/jats:sup>\/l. Nonhematological toxicity was minimal. In conclusion, FLAG is an active and tolerable combination in refractory ALL, particularly in cases with myeloid antigen expression where G\u2010CSF appears to improve efficacy, probably increasing ara\u2010C incorporation into the DNA of leukemic cells.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1996.tb00720.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T05:21:28Z","timestamp":1279430488000},"page":"308-312","source":"Crossref","is-referenced-by-count":26,"title":["FLAG (Fludarabine, Cytarabine, G\u2010CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: <i>in vitro<\/i> and <i>in vivo<\/i> effects"],"prefix":"10.1111","volume":"56","author":[{"given":"Giuseppe","family":"Visani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Manfroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annarita","family":"Cenacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marino","family":"Clavio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sante","family":"Tura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood.V73.8.2051.2051","article-title":"Acute lymphoblastic leukemia: recent advances in biology and therapy","volume":"73","author":"Champlin R.","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-0609.1985.tb00748.x","article-title":"Intermediate and high dose Ara\u2010C and m\u2010Amsa (or Daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukemia and lymphoblastic non\u2010Hodgkin lymphoma","volume":"34","author":"Willemze R.","year":"1985","journal-title":"Scand J Hematol"},{"key":"e_1_2_1_4_2","first-page":"87","article-title":"Cytosine Arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia","volume":"14","author":"Hiddeman W.","year":"1987","journal-title":"Semin Oncol"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood.V72.2.433.bloodjournal722433","article-title":"Amsacrine with high\u2010dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults","volume":"72","author":"Arlin ZA","year":"1988","journal-title":"Blood"},{"key":"e_1_2_1_6_2","first-page":"637","article-title":"Treatment of refractory acute lymphoblastic leukemia in adults with high dose Cytosine Arabinoside and mitoxantrone (HAM)","volume":"4","author":"Hiddeman W.","year":"1990","journal-title":"Leukemia"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900101)65:1<5::AID-CNCR2820650104>3.0.CO;2-R"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/oxfordjournals.annonc.a057675","article-title":"Idarubicin and high\u2010dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia","volume":"1","author":"Giona F.","year":"1990","journal-title":"Ann Oncol"},{"key":"e_1_2_1_9_2","first-page":"69","article-title":"Treatment of relapsed or refractory adult acute lymphoblastic leukemia","volume":"709","author":"Freund N.","year":"1992","journal-title":"Cancer"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb03252.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01714952"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.1.28"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.116"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309148532"},{"key":"e_1_2_1_15_2","first-page":"2076","article-title":"Fludarabine + Ara\u2010C + G\u2010CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells","volume":"8","author":"Tosi P.","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931001)72:7<2155::AID-CNCR2820720715>3.0.CO;2-V"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1994.12.4.671","article-title":"Use of G\u2010CSF before, during and after Fludarabine + Ara\u2010C induction therapy of newly\u2010diagnosed AML or MDS: comparison with Fludarabine + Ara\u2010C without G\u2010CSF","volume":"4","author":"Estey E.","year":"1994","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_18_2","first-page":"1842","article-title":"FLAG (Fludarabine + High dose Cytarabine +G\u2010CSF): an effective and tolerable protocol for the treatment of \u2018poor risk\u2019 acute myeloid leukemias","volume":"8","author":"Visani G.","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V60.3.677.677","article-title":"Adolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy. A study of 293 patients","volume":"63","author":"Baccarani M.","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_20_2","first-page":"101","article-title":"Characterization of DNA binding protein released from S180 chromatin during brief digestion with DNAse I","author":"Ponde CK","year":"1987","journal-title":"Mol Cell Biochem"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1016\/S0021-9258(17)46267-3","article-title":"Incorporation of 9\u2010b\u2010arabinofuranosyl\u20102\u2010fluoroadenine into DNA and its chain termination: effect on DNA synthesis","volume":"265","author":"Huang P.","year":"1990","journal-title":"J Biol Chem"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb08306.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830470410"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103213241204"},{"key":"e_1_2_1_25_2","first-page":"637","article-title":"Review of incidence and clinical relevance of myeloid antigens\u2010positive acute lymphoblastic leukemia","volume":"5","author":"Drexler HG","year":"1991","journal-title":"Leukemia"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03094.x"},{"key":"e_1_2_1_27_2","first-page":"1380","article-title":"Myeloid\u2010antigens expression in childhood acute lymphoblastic leukemia","volume":"325","author":"Tsuchiya H.","year":"1991","journal-title":"N Engl J Med"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood.V77.2.411a.411a","article-title":"Responses to granulocyte colony\u2010stimulating factor (G\u2010CSF) and granulocyte\u2010macrophage CSF in Phi\u2010positive acute lymphoblastic leukemia with myeloid surface markers","volume":"77","author":"Tsuchiya H.","year":"1991","journal-title":"Blood"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1996.tb00720.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1996.tb00720.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T01:45:39Z","timestamp":1698371139000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1996.tb00720.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1996,5]]}},"alternative-id":["10.1111\/j.1600-0609.1996.tb00720.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1996.tb00720.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,5]]}}}